Abstract
11051 Background: Plasma from pts with cancer contains cell free DNA (cfDNA) that can be interrogated by next generation sequencing (NGS). We assessed the use of plasma NGS as a multi-purpose biomarker in advanced cancer pts referred for Phase I trial participation. Methods: Between 12/2012 and 12/2013, the plasma of pts with known mutations in tumor biopsies completing at least 2 courses of investigational targeted drug therapy was collected monthly until disease progression. cfDNA was extracted and NGS performed on the PGM platform with the Ion AmpliSeq Cancer Hotspot Panel v2 starting from 10ng of DNA. This panel amplifies 207 amplicons covering 2,800 COSMIC mutations from 50 oncogenes and tumor suppressors. Results: The mean sequencing coverage across the experiments was 1,685x. Overall, 37 pts (colon (n=11), ovary (10), breast (7), bladder (2), kidney (2), glioblastoma (2), endometrium/melanoma/penile/lung (n=1) receiving inhibitors of the PI3K-AKT-mTOR pathway (n=23), MEK (n=7), PARP (n=3)) or other...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
